Chinese study results in Cancer Management/Prevention

From: Jeff Green (jeffgreen9999_at_yahoo.com)
Date: 11/10/04 

Date: 10 Nov 2004 13:12:43 -0800

Learn More @ www.musclefuel.freelife.com

Cancer Management
Usual dosage level: 4 - 8 oz. daily
In one of the most positive studies yet conducted with goji, 79
advanced cancer patients were treated with the drug LAK/IL-2 combined
with goji LBPs in a clinical trail studied by Cao GW et al (1994) at
Second Military Medical University in Shanghai, China.
Their initial results indicated an amazing regression of cancer in
patients with malignant melanoma, renal cell carcinoma, colorectal
carcinoma, lung cancer, nasopharyngeal carcinoma and malignant
hydrothorax. The response rate was an astonishing 40.9 percent for the
patients treated with LAK/IL-2 plus goji LBP, while the response rate
for patients treated with LAK/IL-2 alone was only 16.1 percent. They
also observed that the remission of cancers in patients treated with
LAK/IL-2 plus goji lasted significantly longer than those treated
without goji. Their results indicated that goji berry polysaccharides
can be used as an adjuvant in cancer therapy.
Another study from China showed LBP increased the sensitivity to
radiation therapy and enhanced the immune system for cancer patients.
In one study on a group of cancer patients, the goji berry triggered
an increase in both lymphocyte transformation rate and white blood
cell count (measures of immune function).
The effect and the mechanism of LBP on inhibiting the growth of human
leukemia HL-60 cells were examined. LBP could inhibit the growth of
these leukemia cells, and also could induce their death (apoptosis).
Lewis Lung cancer cells were transplanted in C57 BL mice, and the
anticancer effects of both goji polysaccharides and radiation were
measured. Following the test, it was concluded that goji enhanced the
effects of radiation in combating Lewis Lung cancer.

Cancer Prevention
Usual dosage level: 2 oz. daily
Interleukin-2 (IL-2) is a crucial cytokine (cell protein) that induces
potent antitumor responses in a variety of cancer models. Several
plant polysaccharides have been shown to enhance the production of
interleukin-2 (IL-2). Goji LBPs are particularly active in this
regard; the enhancing effect of LBP on IL-2 activity was reported by
the Institute of Pharmacology and Toxicology in Beijing (1989). In the
U.S., IL-2 has been under study as an immune promoting factor since
1983, used for some cancers and for HIV infection.
Other studies from China show that goji berry inhibits the gene
mutation induced by TA98 and TA100. Some scientists believe that goji
may be a very good supplement to prevent liver cancer because it
exerts liver protection and anticancer effects at the same time.

Immunity
Usual dosage level: 2 - 4 oz. daily
In a review of research on the goji berry appearing in Recent Advances
in Chinese Herbal Drugs, Dr. Zhou Jinhuang points out that
polysaccharides from goji berries enhance cell-mediated and humoral
immune responses.
Even at a dose of just 5-10 mg/kg daily for one week (equivalent to 2
- 4 oz. of standardized goji juice), LBP polysaccharides could
increase activity of the body's most powerful disease-fighting immune
cells (T-cells, cytotoxic T-cells and natural killer cells) in
laboratory animals. Many studies have shown the goji berry to
increase the lymphocyte transformation rate and improve the macrophage
phagocytic function in animals. LBP assists spleen lymphocyte
transformation induced by Concavalin A. LBP increases the antibody
reaction to T-cell-dependent antigen (SRBC), which means that LBP
selectively strengthens the T-cell immune response. LBP enhances the
T-cell immune response by increasing the number of E receptors on the
surface of T-cells or increasing the numbers of T-cells directly.
LBP also can be used to reduce lead toxicity because it inhibits the
reduction of T-cells and delayed allergy activity induced by lead.
One study was done on seniors in China. This study showed after taking
goji berries, lysozyme, IgG and IgA in serum increased in all
participants. The activity of interleukin 2 (IL-2) was found to
increase 2.26 fold in two-thirds of the participants.

Learn More @ www.musclefuel.freelife.com